Want to see KR:101140 full AI Analyst Report?
INBIOGEN CO., Ltd. (101140) Financial Statements
INBIOGEN CO., Ltd. Financial Overview
INBIOGEN CO., Ltd.'s market cap is currently $45.98B. The company's EPS TTM is $-4161.70; its P/E ratio is -1.11; INBIOGEN CO., Ltd. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 6.30B | $ 7.04B | $ 6.24B | $ 11.40B | $ 10.48B |
| Gross Profit | $ -574.39M | $ 660.07M | $ 1.28B | $ 2.56B | $ 1.96B |
| Operating Income | $ -4.33B | $ -6.09B | $ -6.15B | $ 44.02B | $ -7.69B |
| EBITDA | $ -3.97B | $ 17.23B | $ 13.34B | $ 45.46B | $ 116.01B |
| Net Income | $ 5.82B | $ 16.12B | $ 18.86B | $ -119.69B | $ 94.12B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 901.70M | $ 5.72B | $ 6.09B | $ 9.29B | $ 23.15B |
| Total Assets | $ 159.99B | $ 162.73B | $ 151.31B | $ 141.81B | $ 274.47B |
| Total Debt | $ 1.17B | $ 894.79M | $ 593.26M | $ 1.77B | $ 13.41B |
| Net Debt | $ 266.07M | $ -4.82B | $ -5.50B | $ -7.52B | $ -9.74B |
| Total Liabilities | $ 2.35B | $ 2.89B | $ 2.62B | $ 37.40B | $ 96.45B |
| Stockholders' Equity | $ 157.64B | $ 159.84B | $ 148.68B | $ 104.42B | $ 178.02B |
| Cash Flow | |||||
| Free Cash Flow | $ -5.60B | $ -117.41M | $ -1.38B | $ -11.84B | $ -9.47B |
| Operating Cash Flow | $ -5.55B | $ -33.13M | $ -1.05B | $ -11.51B | $ -7.07B |
| Investing Cash Flow | $ 466.48M | $ -74.22M | $ -192.72M | $ -15.92B | $ -40.44B |
| Financing Cash Flow | $ 272.97M | $ -265.30M | $ -1.96B | $ 13.57B | $ 61.54B |
Currency in KRW